insulin + metformin + polyethylene glycol loxenatide

This is a fixed-dose combination therapy consisting of three active pharmaceutical ingredients used in the management of type 2 diabetes mellitus: - **Insulin** is a peptide hormone that regulates blood glucose by promoting cellular uptake of glucose and inhibiting hepatic glucose production. - **Metformin** is a biguanide oral antihyperglycemic agent that decreases hepatic gluconeogenesis, increases peripheral insulin sensitivity, and reduces intestinal absorption of glucose[3][6][9]. - **Polyethylene glycol loxenatide (PEG-Loxe)** is a long-acting glucagon-like peptide 1 receptor agonist (GLP-1RA), derived from exendin-4 and modified with polyethylene glycol to extend its half-life. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and promotes weight loss[7][10]. The combination targets multiple pathophysiological mechanisms in type 2 diabetes—insulin deficiency/resistance (insulin), impaired hepatic regulation (metformin), and incretin pathway dysfunction (PEG-loxenatide). PEG-loxenatide has demonstrated efficacy both as monotherapy and in combination with metformin for glycemic control and weight reduction[7][10]. This triple therapy may be considered for patients inadequately controlled on dual or monotherapy.